Company News
Suven Life Sciences SUVN-I6107 Phase-1 Study Success
Suven Life Sciences announced successful completion of First-in-Human Phase-1 clinical study for its novel CNS drug candidate SUVN-I6107.
The study demonstrated favorable safety profile with no dose-l
